Effects of blastocoelic expansion and plasminogen activator activity on hatching and zona pellucida solubility in bovine embryos in vitro.
Two experiments were conducted to evaluate factors affecting zona pellucida (ZP) solubility in bovine embryos during hatching in vitro. In Exp. 1, the relationship between blastocoelic expansion and ZP solubility was determined. Day-6 embryos (n = 42) with good or excellent quality grades were cultured (Cultured embryos), whereas embryos of fair quality (Not-cultured embryos) were immediately placed in .2% SDS, and the time required for complete dissolution of the ZP (ZPDT) was determined. For Cultured embryos, ZPDT was determined after 192 h of in vitro development. Zona pellucida dissolution time was greater (P < .05) in Not-cultured embryos than in Cultured embryos and negatively correlated (P < .01) with changes in embryonic surface area. In Exp. 2, the effects of suppressing plasminogen activator (PA) activity and blastocoelic expansion on hatching and ZP solubility were examined. Day-6 embryos (n = 99) were cultured in medium containing 0, 10, or 100 IU/mL of human PA inhibitor-2 (PAI-2) and incubated for 24 to 44 h in medium containing 0, .1, or .5 nM ouabain. Percentages of embryos hatching were not different (P > .05) among 0, 10, and 100 IU/mL of PAI-2; however, more (P < .05) embryos hatched after exposure to 0 and .1 nM ouabain than to .5 nM ouabain. Embryonic PA activity was suppressed (P < .05) by PAI-2, whereas exposure to ouabain did not affect (P > .05) PA activity. Mean ZPDT did not differ (P > .05) following culture in medium containing PAI-2 or exposure to ouabain.(ABSTRACT TRUNCATED AT 250 WORDS)
Coates
A A
AA
Department of Animal Sciences, Oregon State University, Corvallis 97331-6702.
Menino
A R
AR
D000818:Animals; D001755:Blastocyst / Q000502:physiology*; D002417:Cattle / Q000196:embryology*; D004622:Embryo, Mammalian / Q000502:physiology; D005314:Embryonic and Fetal Development / Q000502:physiology*; D005260:Female; D066298:In Vitro Techniques; D010042:Ouabain / Q000494:pharmacology; D017396:Plasminogen Activator Inhibitor 2 / Q000494:pharmacology; D010960:Plasminogen Activators / Q000502:physiology*; D011247:Pregnancy; D011897:Random Allocation; D012995:Solubility; D015044:Zona Pellucida / Q000502:physiology*
D017396:Plasminogen Activator Inhibitor 2; D010042:Ouabain; D010960:Plasminogen Activators